IGF2 Protein (AA 25-91)

Catalog No. ABIN2666937

Recombinant IGF2 protein expressed in Escherichia coli (E. coli).

Quick Overview for IGF2 Protein (AA 25-91) (ABIN2666937)

Target: IGF2 (Insulin-Like Growth Factor 2 (IGF2))

Protein Type: Recombinant

Biological Activity: Active

Origin: Mouse

Source: Escherichia coli (E. coli)

Application: ELISA, Flow Cytometry (FACS)

Purity: > 98 % , as determined by Coomassie stained SDS-PAGE.

Product Details

Protein Characteristics: AA 25-91

Sterility: 0.22 μm filtered

Endotoxin Level:

Less than 1.0 EU per μg cytokine as determined by the LAL method.

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Comment:

Biological activity: ED50 = 10 - 30 ng/ml, corresponding to a specific activity of 0.3 - 1 x 105 units/mg, as determined by the dose dependent stimulation of MCF-7 cell proliferation.

Restrictions: For Research Use only

Handling

Format: Liquid

Reconstitution: For maximum results, quick spin vial prior to opening. Stock solutions should be prepared at no less than 10 μg/mL in sterile buffer (PBS, HPBS, DPBS, and EBSS) containing carrier protein such as 1 % BSA or HSA. After dilution, the cytokine can be stored between 2 °C and 8 °C for one month or from -20 °C to -70 °C for up to 3 months.

Buffer: 0.22 μm filtered protein solution is in 5 mM citric acid, 5 mM NaHPO4 , 0.15 M NaCl, pH 3.0.

Handling Advice: Avoid repeated freeze/thaw cycles.

Storage: -20 °C

Storage Comment: Unopened vial can be stored between 2°C and 8°C for three months, at -20°C for six months, or at -70°C for one year.

Target Details

Target: IGF2 (Insulin-Like Growth Factor 2 (IGF2))

Alternative Name: IGF-II

Background: IGF-II is a member of the IGF family that is comprised of three members (IGF-I, IGF-II, and insulin). IGF-I and IGF-II share approximately 50 % similarity with insulin at the amino acid level. IGF-II is synthesized as a 180 amino acid in the pro-IGF-II form, pro-IGF-II is processed to the mature, active protein with the help of glucose regulating protein 94 (GRP94) that possesses chaperone activity towards IGF-II. GRP94 and IGF-II play a key role in muscle differentiation. Seven binding proteins have been described (IGFBP-1 to -7). IGFBPs extend the half life and regulate the availability of the IGFI and IGFII. It has been described that IGFBP3 is the main circulating binding protein for IGFs, in serum approximately 75 % of circulating IGF-I and IGF-II bind to IGFBP3 and the co-carrier acid labile subunit (ALS). IGF-II binds to three receptors, and the binding to IGFIR promotes cell proliferation, survival, differentiation, and migration as well as metabolic function of IGF-II. Embryonic stem cell differentiation into endothelial cells is promoted by the binding of IGF-II to IGFR1. IGF-II binding to IGF-IIR induces internalization and clearing of IGF-II. Osteogenic differentiation and bone formation is enhanced by IGF-II through bone morphogenetic protein-9 (BMP-9). Polymorphisms of IGF-II are associated with obesity, cardiovascular risk factors, and hypertension.

Molecular Weight: The 67 amino acid recombinant protein has a predicted molecular mass of approximately 7.4 kDa. The DTT-reduced and non-reduced protein migrate at approximately 9 kDa by SDS-PAGE. The N-terminal amino acid is Ala.

Pathways: Hormone Activity, Regulation of Hormone Metabolic Process, Regulation of Hormone Biosynthetic Process, Regulation of Carbohydrate Metabolic Process, Activated T Cell Proliferation